ASCO 2021 Solid Tumors – Roberto Pazo-Cid
Roberto Pazo-Cid outlines recent insights gained in terms of anti-PD-1 treatment in the setting of esophageal squamous cell carcinoma, talks about the practice-changing results obtained in the CheckMate 649 trial and the impact of PD-1 inhibition on the real-world prognosis of patients with gastric and esophageal adenocarcinoma as well as further developments regarding immune checkpoint inhibition.
Here is the full ASCO 2021 Solid Tumors report.
More posts
Early insights for CPI combinations in solid tumors
Early insights for CPI combinations in solid tumors Ezabenlimab combined with a
Anti-PD-1 compounds targeting MSI-H/dMMR tumors
Anti-PD-1 compounds targeting MSI-H/dMMR tumors Keynote-158: an update of pembr
PARP- and anti-PD-1-based strategies in breast and cervical cancer
PARP- and anti-PD-1-based strategies in breast and cervical cancer Talazoparib
Checkpoint inhibition: predictors, resistance and immunogenomic features
Checkpoint inhibition: predictors, resistance and immunogenomic features Predic
Novel approaches in gastric cancer
Novel approaches in gastric cancer LEAP-005: lenvatinib plus pembrolizumab in g
Preface ASCO Solid Tumor 2021
Preface ASCO Solid Tumor 2021 Ian Chau, MD, Department of Medicine, The Royal M
